Chapter 24 — Key Takeaways

The one-paragraph version

A research program aimed at producing a tan without ultraviolet light produced, by way of an unexpected observation, an approved treatment for a sexual desire disorder — and, from the same line, an approved treatment for a rare photosensitivity disease and an unapproved compound sold on the internet with a melanoma signal attached. All three act on the same five-member receptor family, and which effect you get depends entirely on which receptor subtype is engaged and which tissue it sits in. The chapter's most immediately useful content is the distinction between drugs that act on blood flow and drugs that act on desire; the chapter's most important lesson about evidence is that bremelanotide's ✅ means the evidence supports this claim in this population and not this drug is dramatic.

The receptor map

• MC1R — melanocytes; pigmentation. MC2R — adrenal cortex; responds to ACTH. MC3R / MC4R — central nervous system; energy balance and sexual function. MC5R — exocrine and sebaceous glands.
• A nonselective melanocortin agonist hits several of these at once. That is the map working as drawn, not a malfunction.
• This is why an MC4R obesity drug causes hyperpigmentation and a sexual-function drug lists focal hyperpigmentation on its label. Both are on-target effects at a different subtype.
• One peptide family produces pigmentation, adrenal output, appetite suppression, sebum, and sexual arousal. Chapter 2's claim that effect is a property of the listener, not the ligand, is literally true here.
• The precursor proopiomelanocortin yields α-MSH, ACTH, and β-endorphin. One gene, one precursor, several unrelated hormones.

The molecule

• Bremelanotide (PT-141): a cyclic heptapeptide, roughly 1,025 Da, closed by a lactam bridge, containing a D-amino acid and a non-standard residue. Cyclization raises potency and slows degradation; the D-residue defeats stereospecific proteases.
• Melanotan II is the same cyclic heptapeptide with a different C-terminus. One functional group separates an approved medicine from a gray-market tanning compound — which means structural near-identity carries no evidentiary weight either.

The distinction that matters most (§24.3)

• Sexual function is not one variable. Desire, arousal, orgasm, and absence of pain are partly independent, and any one can be impaired with the others intact.
• PDE5 inhibitors act peripherally, on genital vascular smooth muscle, sustaining a response that arousal has already begun. They cannot initiate anything.
• Bremelanotide acts centrally, on melanocortin receptors in circuits associated with sexual motivation. It does nothing to a blood vessel.
• They are not interchangeable and not competitors. A vascular drug does not help a desire problem; a central drug does not help a flow problem.
• The sorting question is roughly: is the interest there and the response missing, or is the interest itself absent?
• "The female Viagra" is wrong three times — wrong about mechanism, wrong about the target complaint, and wrong about magnitude. The third error does the most damage, because it sets up an expectation the drug cannot meet.
• A response problem can be an early sign of vascular disease elsewhere, which is why treating it purely as a bedroom issue can mean missing something.

The approval, stated honestly

• Bremelanotide (Vyleesi) is approved for hypoactive sexual desire disorder in premenopausal women, taken as needed rather than daily.
• The population is narrow: it excludes postmenopausal women, excludes men, and excludes low desire better explained by another condition, a medication, or relationship circumstances.
• The evidence is two randomized, double-blind, placebo-controlled trials using validated desire and distress instruments. Both co-primary endpoints separated from placebo.
• The effect was statistically significant and modest — fractions of a point on multi-point scales, against a substantial placebo response. The number of satisfying sexual events did not separate from placebo.
• Nausea is common — a large minority of participants. For a drug taken in anticipation of sexual activity, that is a meaningful practical limitation, not a routine tolerability note.
• Also on the label: transient blood pressure increase and heart rate decrease, contraindication in uncontrolled hypertension and known cardiovascular disease, and focal hyperpigmentation.

HSDD

• The diagnosis requires distress. Low desire that does not trouble the person is not a disorder. Popular coverage drops this clause constantly, and dropping it is the source of most of the confusion.
• Critics argue it converts normal variation into pathology, that its promotion has been commercially entangled, that a distress criterion can manufacture its own denominator, and that it locates relational problems inside one person.
• Proponents argue that distressing low desire is real and durable, that the distress criterion is a safeguard rather than a loophole, that every criticism applies equally to insomnia, and that refusing the diagnosis abandons patients — disproportionately women — to a long history of having their complaints treated as character.
• The dispute is not primarily empirical. It is Chapter 12's disease/behavior/environment frame applied to desire.
• Rule 4 — never downgrade with distaste — governs. You may reject the category and still owe the trials an accurate reading.

Afamelanotide

• Approved to increase pain-free light exposure in erythropoietic protoporphyria — a rare disorder in which accumulated protoporphyrin IX absorbs visible light and produces severe burning pain within minutes.
• It works exactly where the map predicts: MC1R agonism drives eumelanin production, putting a photoprotective layer between light and the molecule that reacts to it. It does not fix the enzyme deficiency.
• Trial endpoint: time in direct sunlight without pain. It increased.
• A narrow ✅ is often more trustworthy than a broad one — the narrower the claim, the more likely the trial actually tested it.
• Its existence is what lets the chapter argue about melanotan II without generalizing to the whole receptor family.

Melanotan II

• Not approved as a medicine in any major jurisdiction. Widely sold and used for cosmetic tanning.
• The concern: it stimulates melanocytes, and melanocytes are the cell of origin of melanoma. Repeated unregulated stimulation, without supervision, in people who often carry elevated melanoma risk to begin with, is a genuine theoretical hazard.
• Published case reports describe darkening and enlarging nevi, eruptive melanocytic lesions, atypical lesions, and melanoma in users. Also reported: nausea, flushing, spontaneous erections, and less commonly rhabdomyolysis and renal complications.
• These establish a signal warranting concern. They do not establish a quantified risk. Nobody can give you the number, in either direction.
• This is precisely the asymmetry from Chapter 5 §5.2: case reports are near-useless for efficacy and genuinely valuable for rare, distinctive harms — because the two inference problems require different things.
• A second, separate risk category applies to any unapproved injectable from unregulated channels: identity, purity, concentration, sterility, and endotoxin are all unverified (Chapters 19 and 34).

Kisspeptin

• Acts through KISS1R, upstream of GnRH, and is essential for activation of the reproductive axis. Loss-of-function mutations cause failure of puberty — about as clean a demonstration of necessity as human physiology offers.
• GnRH must be pulsatile; continuous stimulation suppresses the axis, which is the therapeutic basis of the -relin drug class. A peptide whose value depends on reproducing a rhythm has a hard pharmacokinetic problem.
• Under investigation in reproductive medicine and, at an earlier stage, in sexual and emotional processing. Real science, openly conducted, no approved indication.
• The honest counterpart to melanotan II: both have beautiful mechanisms; only one is being sold.

The ratings

The four lessons buried in that table:

1. One family, four ratings. Ratings attach to claims, not to molecules or families (rule 1).
2. The two ✅s say the same thing about evidence and different things about magnitude. ✅ certifies support, not drama.
3. The two ❌s have different structures. One marks an inference beyond the data; the other marks absent data plus a harm signal. The symbol underdetermines the meaning, which is why every rating needs its one-sentence reason.
4. Nothing was rated on how it sounds (rules 2 and 4).

Dossier — Field 7

• Field 7 records regulatory status and approved indication: approved or not, for what, and for whom — including the exclusions.
• Breadth of use is not breadth of approval. Bremelanotide is the demonstration: an approval covering one diagnosis in one hormonal-status group, alongside marketing, telehealth prescribing, and gray-market sale that extend far past it.
• Off-label prescribing is legal, common, and often appropriate — and generates no evidence. Field 7 records where the evidence stops, and that boundary does not move when a prescription is written.
• "Research use only" is not a statement about quality. It is a statement about jurisdiction.

Closing Part IV

Part IV has been a sequence of near-misses: molecules with well-mapped physiology repeatedly blocked by the blood-brain barrier, by the difference between a pulse and a flat infusion, and by the gap between changing a mechanism and changing an outcome. Bremelanotide is the part's one clear approval — narrow label, modest effect, common adverse effect. That is an accurate ending rather than a discouraging one, and accuracy about the difficulty is what makes the field's real successes worth taking seriously.